SCHEMBL29967929

SCHEMBL29967929

O=S(=O)(NCCNCC=Cc1ccc(Br)cc1)c1cccc2cnccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKACA P17612 6/20 1.00
PRKCG P05129 5/20 1.00
PRKCZ Q05513 5/20 1.00
PRKCD Q05655 5/20 1.00
ROCK2 O75116 4/20 1.00
PRKACG P22612 4/20 1.00
PRKACB P22694 4/20 1.00
PRKD3 O94806 4/20 1.00
PRKCB P05771 4/20 1.00
PRKCA P17252 4/20 1.00
PRKCH P24723 4/20 1.00
PRKCI P41743 4/20 1.00
PRKCE Q02156 4/20 1.00
PRKCQ Q04759 4/20 1.00
PRKD1 Q15139 4/20 1.00
MAPK1 P28482 3/20 1.00
AKT2 P31751 3/20 1.00
AKT3 Q9Y243 3/20 1.00
SMN1; SMN2 Q16637 3/20 1.00
CYP3A4 P08684 3/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL123495 1.00 PRKACA (1.00) PRKACAPRKCGPRKCZPRKCDROCK2
SCHEMBL123496 1.00 PRKACA (1.00) PRKACAPRKCGPRKCZPRKCDROCK2
Hydrochloric Acid SCHEMBL29967768 0.99 PRKACA (1.00) PRKACAPRKCGPRKCZPRKCDROCK2
Bromide SCHEMBL3347119 0.99 PRKACA (0.98) PRKACAPRKCGPRKCZPRKCDROCK2
Bromide SCHEMBL3347113 0.99 PRKACA (0.98) PRKACAPRKCGPRKCZPRKCDROCK2
Hydrochloric Acid SCHEMBL29664044 0.99 PRKACA (1.00) PRKACAPRKCGPRKCZPRKCDROCK2
Hydrochloric Acid SCHEMBL1048972 0.99 PRKACA (1.00) PRKACAPRKCGPRKCZPRKCDROCK2
Hydrochloric Acid SCHEMBL905696 0.99 PRKACA (1.00) PRKACAPRKCGPRKCZPRKCDROCK2
Hydrochloric Acid SCHEMBL1048974 0.99 PRKACA (1.00) PRKACAPRKCGPRKCZPRKCDROCK2
SCHEMBL9636264 0.91 PRKACA (0.83) PRKACAPRKCGPRKCZPRKCDROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4662319-A2 PERSONALIZED CRISPR PROFILING FOR CANCER Integrate Bioscience LLC (US) 2025-12-17 EP disclosed
WO-2024189434-A1 USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) 2024-09-19 WO disclosed
WO-2024168301-A2 PERSONALIZED CRISPR PROFILING FOR CANCER FUNCTION ONCOLOGY, INC. (US) 2024-08-15 WO disclosed
CN-117999073-A Use of nadolol to treat chronic obstructive pulmonary disease by blocking the inhibitor protein-2 pathway 慢性呼吸道治疗有限公司 2024-05-07 CN disclosed
EP-4304717-A1 USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY Chronic Airway Therapeutics Limited (AU) 2024-01-17 EP disclosed
WO-2022192252-A1 USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) 2022-09-15 WO disclosed